Therapy With Bispecific Antibody for EGFR Exon 20 Insertion–Mutated NSCLC

This roundtable series reviews the use of treatment targeting EGFR exon 20 insertion mutations in patients with locally advanced or metastatic non–small cell lung cancer, as discussed by participants at virtual live events.